Effect of clomipramine on myotonia

Antonini, Giovanni; Vichi, R.; Leardi, M. G.; Pennisi, E.; Monza, G. C.; Millefiorini, M

doi:10.1212/wnl.40.9.1473

Cited by 9 publications

(10 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…See Tables: Characteristics of included studies and Characteristics of excluded studies. The original search revealed nine trials that compared active drug treatment with placebo for the treatment of myotonia, in a total of 103 participants with myotonic dystrophy type 1 and 30 participants with myotonia congenita (Antonini 1990;Durelli 1983;Kratz 1986;Gascon 1989;Grant 1987;Kwiecinski 1992;Lewis 1966;Leyburn 1960;Munsat 1967). One trial was found that compared two different drug treatments for the treatment of myotonia, in 10 participants with myotonic dystrophy type 1 (Finlay 1982).…”

Section: Description Of Studiesmentioning

confidence: 99%

“…All included trials were performed in a single centre and a total of 143 participants received treatment (active drug or placebo) over two weeks to six months. In Antonini 1990 the treatment period was separated by a 30-day period washout interval. The other nine trials had no washout interval between the treatment periods.…”

Section: Trial Designmentioning

confidence: 99%

“…The most frequently used outcome measure was the clinical relaxation time in seconds. It was measured after three seconds (Antonini 1990), two to three seconds (Gascon 1989), five seconds (Lewis 1966) and three minutes (Finlay 1982) of maximum voluntary contraction (MVC). Others (Grant 1987;Kratz 1986; Kwiecinski 1992) did not specify the length of maximum voluntary contraction.…”

Section: Outcome Measuresmentioning

confidence: 99%

“…In only three trials the blinding was considered adequate (Durelli 1983;Kwiecinski 1992;Munsat 1967). In six trials the blinding was unclear because it was not described (Antonini 1990;Gascon 1989;Grant 1987;Kratz 1986;Lewis 1966;Leyburn 1960) and in Finlay 1982 the patient blinding was inadequate because participants could recognise the side effects having used the medication previously in a clinical setting. Observer blinding was also intended in at least nine trials.…”

Section: Risk Of Bias In Included Studiesmentioning

confidence: 99%

See 3 more Smart Citations

Drug treatment for myotonia

Trip

Drost

Engelen

et al. 2006

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Due to insufficient good quality data and lack of randomised studies, it is impossible to determine whether drug treatment is safe and effective in the treatment of myotonia. Small single studies give an indication that clomipramine and imipramine have a short-term beneficial effect and that taurine has a long-term beneficial effect on myotonia. Larger, well-designed randomised controlled trials are needed to assess the efficacy and tolerability of drug treatment for myotonia.

show abstract

Section: Description Of Studiesmentioning

confidence: 99%

Section: Trial Designmentioning

confidence: 99%

Section: Outcome Measuresmentioning

confidence: 99%

Section: Risk Of Bias In Included Studiesmentioning

confidence: 99%

See 2 more Smart Citations

Drug treatment for myotonia

Trip

Drost

Engelen

et al. 2006

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…Treatment of myotonia has been directed at electrical stabilization of the muscle membrane mainly using antagonists of voltage-dependent sodium channels, responsible for the repetitive electrical activity which characterizes the myotonic phenomenon. Myotonia has been previously assessed by measuring the relaxation time necessary to completely open the fist after maximum voluntary contraction (MCV) [2], by self-evaluation arbitrary scales [3], by functional tests [3,4], and by myotonic afterdischarge after MCV on electromyography (EMG) measurements [3]. However, the variability of the myotonic phenomenon and the "warm-up" effect have made quantification of myotonia difficult.…”

Section: Introductionmentioning

confidence: 99%

Quantitative myotonia assessment: an experimental protocol

Sansone

Marinou

Salvucci

et al. 2000

Neurological Sciences

View full text Add to dashboard Cite

Severe clinical myotonia can be physically disabling and socially impairing but as yet there is no standardized treatment regimen. The aim of our study is to present a protocol to measure myotonia using quantitative muscle assessment measures. The proposed protocol addresses two main issues. Muscle strength is assessed in 8 muscles on the right and on the left using a myometer (QMA, quantitative muscle assessment) and by testing strength manually using the 5-point MRC scale (5 = normal) in 15 muscles on the right and on the left. Grip myotonia is assessed by: (a) measuring 1/2 and 3/4 relaxation times (RT) after maximum voluntary contraction (MVC) using QMA apparatus; (b) functional tests (time to open a fist 10 times, time to open and squeeze the eyes 10 times, time to climb 10 steps starting from a seated position, time to protrude the tongue 10 times, time to step onto a chair 10 times; (c) subjective measures of the severity of myotonia using an arbitrary 4-point scale (0 = absent, 4 = severe); and (d) electromyography (EMG) relaxation times after MVC. Although QMA seems to be a reliable tool to measure myotonia, there are still a number of unsolved issues. Further studies are needed to ensure the ability of QMA to quantify myotonia and to guarantee the reliability of the results for clinical research purposes.

show abstract

The diagnosis and treatment of myotonic disorders

2013

View full text Add to dashboard Cite

Myotonia is a defining clinical symptom and sign common to a relatively small group of muscle diseases, including the myotonic dystrophies and the nondystrophic myotonic disorders. Myotonia can be observed on clinical examination, as can its electrical correlate, myotonic discharges, on electrodiagnostic testing. Research interest in the myotonic disorders continues to expand rapidly, which justifies a review of the scientific bases, clinical manifestations, and numerous therapeutic approaches associated with these disorders. We review the pathomechanisms of myotonia, the clinical features of the dystrophic and nondystrophic myotonic disorders, and the diagnostic approach and treatment options for patients with symptomatic myotonia.

show abstract

Effect of clomipramine on myotonia

Cited by 9 publications

References 0 publications

Drug treatment for myotonia

Drug treatment for myotonia

Quantitative myotonia assessment: an experimental protocol

The diagnosis and treatment of myotonic disorders

Contact Info

Product

Resources

About